What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL.

A. Welt, M. Thill, E. Stickeler, M.-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, A. Wöckel, N. Harbeck, T. Decker, 2020.
Oncol Res Treat. 2020;43 (suppl 4)(130):164.